P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients
暂无分享,去创建一个
Ju-Seog Lee | B. Sohn | M. Finegold | J. Goss | D. Lopez-Terrada | S. Thevananther | J. Maynard | Xiaoying Yu
[1] M. Plummer,et al. International agency for research on cancer. , 2020, Archives of pathology.
[2] Cheng-song Sun,et al. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy , 2015, Acta Pharmacologica Sinica.
[3] Le Xu,et al. Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection , 2015, Tumor Biology.
[4] Ying Zhang,et al. Clinical significance of microRNA 138 and cyclin D3 in hepatocellular carcinoma. , 2015, The Journal of surgical research.
[5] N. Vigneswaran,et al. P2Y2 purinergic receptor activation is essential for efficient hepatocyte proliferation in response to partial hepatectomy. , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[6] J. Dranoff,et al. Expression of mediators of purinergic signaling in human liver cell lines , 2014, Purinergic Signalling.
[7] K. Chang,et al. P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment , 2014, Oncotarget.
[8] P. Song,et al. The P2Y2 Nucleotide Receptor Mediates the Proliferation and Migration of Human Hepatocellular Carcinoma Cells Induced by ATP* , 2014, The Journal of Biological Chemistry.
[9] P. Brouckaert,et al. Extracellular ATP drives systemic inflammation, tissue damage and mortality , 2014, Cell Death and Disease.
[10] F. Di Virgilio,et al. Purinergic signalling and cancer , 2013, Purinergic Signalling.
[11] D. Candinas,et al. Promotion of liver regeneration by natural killer cells in a murine model is dependent on extracellular adenosine triphosphate phosphohydrolysis , 2013, Hepatology.
[12] T. Tordjmann,et al. Innate immunity, purinergic system, and liver regeneration: A trip in complexity , 2013, Hepatology.
[13] W. Pan,et al. Monocyte/macrophage‐elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions , 2013, Hepatology.
[14] M. Shimizu,et al. Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test , 2013, Journal of Cancer Research and Clinical Oncology.
[15] Jan-Gowth Chang,et al. Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma , 2013, Medical Oncology.
[16] V. Sukhatme,et al. Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice , 2013, Hepatology.
[17] S. Imbeaud,et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.
[18] X. Wang,et al. Sixty‐five gene‐based risk score classifier predicts overall survival in hepatocellular carcinoma , 2012, Hepatology.
[19] J. Dranoff,et al. Role of purinergic P2X receptors in the control of liver homeostasis. , 2012, Wiley interdisciplinary reviews. Membrane transport and signaling.
[20] Hao Ren,et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma , 2012, Carcinogenesis.
[21] A. Mehmood,et al. Identification of ionotrophic purinergic receptors in Huh-7 cells and their response towards structural proteins of HCV genotype 3a , 2011, Virology Journal.
[22] K. Jacobson,et al. Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. , 2011, Biochemical pharmacology.
[23] G. Burnstock,et al. P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells , 2011, Molecular and Cellular Endocrinology.
[24] Stephanie Roessler,et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. , 2010, Cancer research.
[25] A. I. Rojo,et al. The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death. , 2010, Free radical biology & medicine.
[26] P. Galle,et al. Future perspectives in hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[27] S. Bhatia,et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States , 2010, Cancer.
[28] Xianglin Shi,et al. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma , 2009, Molecular Cancer.
[29] P. Malfertheiner,et al. Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors , 2009, Digestive Diseases.
[30] R. Fisher,et al. Genes Involved in Viral Carcinogenesis and Tumor Initiation in Hepatitis C Virus-Induced Hepatocellular Carcinoma , 2009, Molecular medicine.
[31] E. Wagner,et al. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.
[32] F. Di Virgilio,et al. Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase , 2008, PloS one.
[33] R. Doctor,et al. Characterization of ionotrophic purinergic receptors in hepatocytes , 2007, Hepatology.
[34] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[35] V. Mazzaferro,et al. Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.
[36] S. Nordgren,et al. P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer. , 2007, Autonomic & autacoid pharmacology.
[37] Y. Sasaki. Does oxidative stress participate in the development of hepatocellular carcinoma? , 2007, Journal of Gastroenterology.
[38] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.
[39] G. Burnstock,et al. P2 receptors and cancer. , 2006, Trends in pharmacological sciences.
[40] D. Cockayne,et al. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP , 2005, The Journal of physiology.
[41] R. Doctor,et al. Purinergic regulation of cholangiocyte secretion: identification of a novel role for P2X receptors. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[42] Vijaya R Arjunan,et al. Extracellular ATP activates c‐jun N‐terminal kinase signaling and cell cycle progression in hepatocytes , 2004, Hepatology.
[43] D. Concas,et al. Loss of cyclin D1 does not inhibit the proliferative response of mouse liver to mitogenic stimuli , 2002, Hepatology.
[44] D. Botstein,et al. Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.
[45] G. Burnstock. Purine-mediated signalling in pain and visceral perception. , 2001, Trends in pharmacological sciences.
[46] T. van Biesen,et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. , 1999, European journal of pharmacology.
[47] W. Stühmer,et al. Molecular characterization and pharmacological properties of the human P2X3 purinoceptor. , 1997, Brain research. Molecular brain research.
[48] D. Samuel,et al. ATP release after partial hepatectomy regulates liver regeneration in the rat. , 2010, Journal of hepatology.
[49] Y. Banz,et al. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. , 2008, Frontiers in bioscience : a journal and virtual library.
[50] J. Fitz,et al. Regulation of cellular ATP release. , 2007, Transactions of the American Clinical and Climatological Association.
[51] H. Friess,et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[52] American Liver Foundation , 2005, Digestive Diseases and Sciences.